Literature DB >> 20567835

Castleman's disease associated with a cerebellar chordoid meningioma and intestinal lymphangiectasia.

Chul Jin Jeon1, Mi Jin Kim, Jong Seung Lee, Ji Hyuk Lee, Doo-Sik Kong, Hyung Jin Shin, Yeon Lim Suh, Kyoung Mee Kim, Yon Ho Choe.   

Abstract

Castleman's disease (CD) is a rare nonneoplastic lymphoproliferative disorder of unknown etiology. It is characterized by enlarged hyperplastic lymph nodes, usually presenting as a localized mass. Although an intracranial location is very uncommon, it should be considered in the differential diagnosis of a chordoid meningioma. We describe a pediatric case of CD with a cerebellar chordoid meningioma and intestinal lymphangiectasia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20567835     DOI: 10.1007/s00381-010-1196-9

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  17 in total

1.  Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations.

Authors:  A R Keller; L Hochholzer; B Castleman
Journal:  Cancer       Date:  1972-03       Impact factor: 6.860

2.  Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease.

Authors:  J Nishi; K Arimura; A Utsunomiya; S Yonezawa; K Kawakami; N Maeno; O Ijichi; N Ikarimoto; M Nakata; I Kitajima; T Fukushige; H Takamatsu; K Miyata; I Maruyama
Journal:  Br J Haematol       Date:  1999-03       Impact factor: 6.998

3.  Chordoid meningioma in a child. Case report.

Authors:  H Kobata; A Kondo; K Iwasaki; H Kusaka; H Ito; S Sawada
Journal:  J Neurosurg       Date:  1998-02       Impact factor: 5.115

Review 4.  Chordoid meningioma with polyclonal gammopathy. Case report.

Authors:  D K Lee; D G Kim; G Choe; J G Chi; H W Jung
Journal:  J Neurosurg       Date:  2001-01       Impact factor: 5.115

5.  Castleman's disease in children: report of 2 cases and clinicopathologic review.

Authors:  David A Palma; A Rashid Dar; Scott J Millington; Cheryl L Smits; Kamilia Rizkalla; Richard Inculet
Journal:  J Pediatr Hematol Oncol       Date:  2004-04       Impact factor: 1.289

6.  Intracranial lesion resembling giant lymph node hyperplasia.

Authors:  M J Lacombe; J Poirier; J P Caron
Journal:  Am J Clin Pathol       Date:  1983-11       Impact factor: 2.493

7.  Interleukin-6 gene expression in Castleman's disease.

Authors:  M B Leger-Ravet; M Peuchmaur; O Devergne; J Audouin; M Raphael; J Van Damme; P Galanaud; J Diebold; D Emilie
Journal:  Blood       Date:  1991-12-01       Impact factor: 22.113

8.  Expression of interleukin-6 in Castleman's disease.

Authors:  S M Hsu; J A Waldron; S S Xie; B Barlogie
Journal:  Hum Pathol       Date:  1993-08       Impact factor: 3.466

9.  Intestinal lymphangiectasia associated with angiofollicular lymph node hyperplasia (Castleman's disease).

Authors:  S F Moss; D M Thomas; C Mulnier; I G McGill; H J Hodgson
Journal:  Gut       Date:  1992-01       Impact factor: 23.059

10.  Elevated levels of tumor necrosis factor-beta, gamma-interferon, and IL-6 mRNA in Castleman's disease.

Authors:  S S Winter; T A Howard; A K Ritchey; F G Keller; R E Ware
Journal:  Med Pediatr Oncol       Date:  1996-01
View more
  3 in total

Review 1.  Predictors of recurrence in the management of chordoid meningioma.

Authors:  Winward Choy; Leonel Ampie; Jonathan B Lamano; Kartik Kesavabhotla; Qinwen Mao; Andrew T Parsa; Orin Bloch
Journal:  J Neurooncol       Date:  2015-09-26       Impact factor: 4.130

Review 2.  Variants of meningiomas: a review of imaging findings and clinical features.

Authors:  Akira Kunimatsu; Natsuko Kunimatsu; Kouhei Kamiya; Masaki Katsura; Harushi Mori; Kuni Ohtomo
Journal:  Jpn J Radiol       Date:  2016-05-02       Impact factor: 2.374

3.  Clinical features and treatment outcome of chordoid meningiomas in a single institute.

Authors:  Tae Keun Jee; Kyung-Il Jo; Ho Jun Seol; Doo-Sik Kong; Jung-Il Lee; Hyung Jin Shin
Journal:  J Korean Neurosurg Soc       Date:  2014-09-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.